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Abstract
Background: Malignancies arising in the large bowel cause the second largest number of deaths from cancer in
the Western World. Despite progresses made during the last decades, colorectal cancer remains one of the most
frequent and deadly neoplasias in the western countries.
Methods: A genomic study of human colorectal cancer has been carried out on a total of 31 tumoral samples,
corresponding to different stages of the disease, and 33 non-tumoral samples. The study was carried out by
hybridisation of the tumour samples against a reference pool of non-tumoral samples using Agilent Human 1A 60-
mer oligo microarrays. The results obtained were validated by qRT-PCR. In the subsequent bioinformatics analysis,
gene networks by means of Bayesian classifiers, variable selection and bootstrap resampling were built. The
consensus among all the induced models produced a hierarchy of dependences and, thus, of variables.
Results: After an exhaustive process of pre-processing to ensure data quality–lost values imputation, probes
quality, data smoothing and intraclass variability filtering–the final dataset comprised a total of 8, 104 probes. Next,
a supervised classification approach and data analysis was carried out to obtain the most relevant genes. Two of
them are directly involved in cancer progression and in particular in colorectal cancer. Finally, a supervised classifier
was induced to classify new unseen samples.
Conclusions: We have developed a tentative model for the diagnosis of colorectal cancer based on a biomarker
panel. Our results indicate that the gene profile described herein can discriminate between non-cancerous and
cancerous samples with 94.45% accuracy using different supervised classifiers (AUC values in the range of 0.997
and 0.955).
Background
Colorectal cancer (CRC), is the third most common
form of cancer and the second leading cause of death
among cancers worldwide, with approximately 1, 000,
000 new cases of CRC and 50, 000 deaths related to
CRC each year [1,2]. Sporadic colon cancer represents
the 70% of newly diagnosed cases, and it is believed to
slowly develop via a progressive accumulation of multi-
ple mutations that affect tumour suppressor genes, as
well as oncogenes or mismatch repair genes (MMR) [3].
Statistics concerning colon cancer survival show dif-
ferences between countries. In US, the overall five-year
survival rate is 62% while in Europe is 43%. The reasons
for this different behaviour are not very clear, although
quality of care and screening programs could play a cen-
tral role in the survival of CRC, since it is well estab-
lished that the stage of the disease at diagnosis greatly
impacts colon cancer survival rates. In this way, the US
Centres for Disease and Control Prevention (CDC) state
that the 5-year survival rate for persons who received a
diagnosis of localized colorectal cancer is 91% compared
with 70% for regional-state cancer and 11% for distant
-stage cancer [4]. Also, a study registered at the National
Cancer Institute’s SEER database, conducted with more
than 28, 000 people diagnosed with colon cancer
between 1998 and 2000, found that the observed 5-year
survival rates related to the stage of the disease at diag-
nosis were the following: I-74%, IIA-67%, IIB-59%, IIC-
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can Cancer Society).
This and other evidences have convinced the scientific
and medical community of the great importance of
screening for CRC to reduce incidence and mortality,
through detection of premalignant polyps as well as
diagnosis of early -stage cancer [4,5]. As a result, data
from the CDC show that CRC incidence and mortality
have experienced a decline in recent years due to the
screening campaigns [6,7]. In spite of this, the same stu-
dies indicate that CRC remains the second most com-
mon cause of cancer deaths after lung cancer in the US
and the leading cause of cancer deaths among non-smo-
kers. In this context, there is a global awareness for the
implementation of CRC screening programmes [8]. Not
only the US, but also France put into action a screening
programme in 2003, Finland in 2004, UK in 2006, etc.
However, there is no international consensus on the
preferred strategy to carry on the screening, mainly due
to the limitations of the available screening techniques
at present.
The currently used methods for the early detection of
CRC are the Faecal Occult Blood Test (FOBT) and the
endoscopy. FOBT is simple, inexpensive and the least
invasive method of screening available. Also, it has been
shown through prospective randomized trials that FOBT
reduces CRC mortality, and consequently the evidence
for its use is robust. However, FOBT presents relatively
high false negative and false positive rates, and it has
particularly poor sensitivity for the detection of early-
stage lesions [9-11]. In an attempt to improve on the
false positive rates of FOBT, a new Faecal Immuno-
chemical testing (FIT) has been developed. It has slightly
superior performance characteristics but at a greatly
increased financial cost, and its implementation has not
been effective as yet [12].
On the other hand, colonoscopy offers significant
improvements in detection rates for CRC but it also has
important disadvantages associated, as inconvenience,
high economic burden and potential major complica-
tions (bleeding, perforation) [13,14].
All this emphasizes the urgent necessity of new diag-
nostic approaches in order to improve the outcome of
CRC screening programs. In particular. there is a clinical
need for identifying specific biomarkers for early detec-
tion of CRC [2,12]. Moreover, there is at the present
time a widespread awareness, not only between scien-
tists and practicing clinicians but also among regulatory
organizations and healthcare systems, that the develop-
ment of biomarkers will offer the major advances in
CRC detection [15]. The scientific world even holds an
expectation that a new generation of molecular markers
should improve compliance with CRC screening in the
same way other markers do in other illnesses screening
programs (lipid monitoring, PSA,...).
The recent advances in genomics and proteomics have
contributed to our molecular understanding of CRC by
evaluating the expression profiles of genes and proteins,
in cancerous and non-cancerous surrounding tissues
and body fluids. The identification of genes and/or pro-
teins that are characteristic of the development of CRC
can render potential biomarkers that will facilitate the
early detection of CRC. There is quite a number of
recently discovered potential molecular biomarkers,
such as CEA, CA 19-9, K-ras,L - D N A ,A P C ,T I M P - 1 ,
NNMT, MIF, PSME3, Septin 9, MMP-9, MMP-7, Spon-
din-2, DcR3, Trail-R2, MICI, CCSA-2, CCSA-3, CCSA-
4, etcetera [16]. Some of them have been questioned
because of insufficient sensitivity or specificity (CEA,
CA 19-9,...), others because of poor performance in
early stages of CRC (TIMP-1,...), and some others
remain promising but there is insufficient evidence for
their routine implementation (CCSA-3, CCSA-4, MIF,
DcR3, Spondin-2,...) [17,18]. Many authors agree that a
panel of biomarkers will be likely necessary to reach
appropriate sensitivity for clinical use as a screening bio-
marker, due to the genetic heterogeneity of CRC [12,19].
Furthermore, a limited number of markers have been
identified to date in CRC, but their individual use has
led to conflicting results [1]. In this context, genomic
techniques, such as DNA microarrays, allow high-
throughput analysis of genes, rendering big volumes of
data which increases the possibilities for uncovering
potential biomarkers. Namely, DNA microarray-based
gene expression profiling technology provides a strategy
to search systematically with a combinatorial manner
for molecular markers of colon cancer.
Our aim in the present study was to develop a model
or biomarker for the objective diagnosis of CRC based
on gene expression patterns. For this purpose, we used
the microarray technology in combination with
advanced statistics analysis techniques. The identifica-
tion of a robust panel of CRC-specific biomarkers
through genomics would be the cornerstone for their
posterior development into non invasive samples-based
diagnosis markers.
Methods
Patients samples
A total of 64 tissue samples–33 non-tumoral tissues
(NT) and 31 tumoral tissues (T)–were obtained from
patients with CRC diagnosed at different stages in
Cruces Hospital (BIOEF) after informed consent. Ethical
approval was obtained from the Clinical Research Ethics
Committee of University Cruces Hospital (reference
number CEIC E02/27).
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ried out to confirm diagnosis as well as tumour staging,
using TNM and Dukes classifications. In TNM system,
stage is expressed in roman numerals from stage I (the
least advanced) to stage IV (the most advanced) and
some stages are subdivided with letters. Dukes classifica-
tion (adapted by Astler and Coller) is an older staging
system that groups patients into either Stage A, B, or C
depending on the extent of the cancer- localized, spread
through the intestinal wall and metastasis to lymph
nodes. Stage D was later added to indicate evidence of
metastases.
None of the patients received neoadjuvant therapy
prior to operation. All the samples were collected in a
tube containing RNAlater solution (Qiagen) to preserve
the RNA from degradation and kept at -80°C until
future use. Clinical features of selected patients are
listed on Additional file 1.
Experimental design
To search for genetic markers, the experimental design
comprised the hybridisation of each sample (both
tumoral and non-tumoral samples) against a reference
pool consisting of the non-tumoral samples [20]. In this
sense, a total of 31 microarrays were hybridised compar-
ing tumoral samples and the pool. In addition, to reduce
the background noise due to variability among non-
tumoral samples, each non-tumoral sample was hybri-
dised against the reference pool. These comprise
another set of 33 microarrays.
RNA isolation
Total RNA was extracted from 64 samples using the
RNeasy Mini kit (Qiagen). RNA quantity and integrity
were determined by the 2, 100 Bioanalyzer (Agilent
Technologies). Using the RIN algorithm (RNA Integrity
Number) as a quality standard, we established a thresh-
old of 5.6 for the selection/inclusion of samples in the
study [21,22].
RNA labelling and array hybridisation
RNA labelling and hybridisation were performed follow-
ing the Agilent Low RNA Input Fluorescent Linear
Amplification kit and Agilent In situ Hybridization kit-
plus. Briefly, reverse transcription was performed on 500
ng of total RNA to synthesize the first and second
strands of cDNA. Next, the cRNA was synthesized by
T7 RNA polymerase which simultaneously incorporates
the fluophores. The pool was labelled with Cyanine-3-
CTP (PerkinElmer), whereas the tumoral and non-
tumoral samples were labelled with Cyanine-5-CTP
(PerkinElmer). Labelled probes were measured in the
spectrophotometer at 550 nm for the samples labelled
with Cy3 and at 650 nm for the ones labelled with Cy5.
In order to determine the efficiency of the labelling
reaction, the ratio of the picomoles of cyanine dye per
μg of cRNA was calculated. Only those labelled samples
with a ratio between 10 and 20 were hybridised.
0.75 μg of labelled cRNA from each sample were
hybridised onto Human 1A Oligo Microarrays 22 K
(Agilent Technologies). The arrays were placed inside
the hybridisation oven (Agilent Technologies) and hybri-
disation reaction was performed for 17 h at 60°C and 4
rpm. The slides were then washed at room temperature
in 20X SSPE and 20% N-laurylsarcosine and dried with
the Stabilization and Drying Solution (Agilent
Technologies).
Scanning and image process
The hybridised arrays were scanned using the GenePix
4000B dual laser slide scanning system (Axon Instru-
ments). The images were processed with the GenePix
Pro 6.0 (Axon), with 10 μm resolution. Microarray inter-
nal controls named ‘N/A’, ‘NegativeControl’, ‘BrightCor-
ner’, ‘Pro25G’ and ‘eQC’ were removed prior to
normalisation. Microarray data are available in http://
www.ebi.ac.uk/arrayexpress under the accession number
E-MTAB-476.
Probes quality pre-processing
Probe quality metrics
Following the quality metrics defined by Chen et al. [23]
we computed three probe quality criteria: fluorescent
intensity measurement, background flatness and signal
intensity consistency qualities. Values of each metric
vary between 0, the lowest, and 1, the maximum. In
order to get the most reliable readings, the global qual-
i t ym e t r i cf o rag i v e np r o b ek was defined as the mini-
mum value of the previous three. In our case, the
acceptance threshold was set up in an average of 0.99
and a total of 11, 120 probes surpassed this stage.
Normalisation
All the readings coming from the probes that surpassed
the quality criteria were smoothed by means of the Low-
ess technique [24]. Lowess normalisation assumes that
the data bias is dependent on spot intensity. The logRa-
tio values are then adjusted subtracting the lowess fit to
the MA-plot from the original logRatio values.
Lost values imputation
Among all the available imputation methods for miss-
ing values, the one that is more broadly used in the
microarray field is the kNN-Impute [25]. In this
method, the classical machine learning kn e a r e s tn e i g h -
bours algorithm is adapted to microarray data. The
imputation algorithm for our data was run with a k
value of 15 neighbours. From the total number of
spots, there were only 1.04% of lost values (7, 534
probes) to imputate.
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A side effect of working with biopsies is that there are
different types of tissues within each sample. This could
lead to great differences in the expression profiles of
particular genes. Thus, the last filtering step dealt with
the assessment of intra-class variability. We removed 3,
016 probes that showed differences greater than 2-fold
between each of the four classes of tissues (non-tumoral,
Dukes B, C and D stages). Therefore, the final dataset
was composed of a total of 8, 104 probes and 64 cases
or microarrays. Figure 1 shows the workflow carried out
during the data filtering process.
Statistical analysis
Analysis of the univariate relevance of each gene
There are several approaches for identifying differen-
tially expressed genes [26]. One common approach is to
look for those genes that show a high differential
expression between phenotypes. In order to identify
such representative set of genes, we firstly performed an
ensemble of univariate relevance rankings. Six non-para-
metric relevance metrics were measured: Mutual infor-
mation, Euclidean distance, Matusita distance, Kullback-
Leibler divergence (with two formulations) and Bhatta-
charyya metric. Each of them provided a relevance rank-
ing of the 8, 104 genes and these rankings were
combined into an ensemble one as a problem of aggre-
gation of individual preferences [27] (Table 1).
Multivariate gene analysis by means of ensemble of
classification models
Univariate approaches are to some extent limited and
they ignore the role of gene combinations that could
provide a good classification. Therefore, our next step
consisted on the selection of a subgroup of relevant
genes that were able to distinguish tumour from non-
tumour samples. This process is known as feature sub-
set selection (FSS) and it is still a growing discipline
[28]. Recent studies show that as important as the clas-
sification accuracy is the behaviour of the FSS approach:
stable approaches should be used instead of those with
a great degree of variance [29]. To accomplish this task,
we performed the ensemble approach proposed by
Armañanzas et al. [30]. This data mining approach
makes use of random resampling of the dataset, a multi-
variate feature subset selection and the induction of a k-
dependence Bayesian network classifier [31]. To seek for
the most stable output, the process is repeated a signifi-
cant number of times in order to reduce the presence of
false positives findings. The output of the method is
comprised by an ensemble of all the induced networks,
that is, a set of high reliability gene expression relation-
ships. This methodological proposal includes a set of
running parameters to be fixed. Especially in the micro-
array domain, all these parameters are expected to set a
scenario in which the running time could be affordable.
Correlation feature selection (CFS) [32] has been widely
ORIGINAL
MICROARRAYS
REMOVE ARRAY
CONTROLS
PROBE QUALITY
METRICS
LOST VALUES
IMPUTATION
INTRACLASS 
DIFFERENCES
UNIVARIATE  
MEASURES
22,574 probes
17,986 probes
11,120 probes
11,120 probes
8,104 probes
CONSENSUS
RANKING
6 univariate rankings
A. B. 
Figure 1 A) Overall data analysis workflow. B) Intraclass dispersion measure for the 11, 120 filtered quality probes.
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Page 4 of 13Table 1 Consensus ranking of the 8,104 probes. In this table the first 50 genes are represented.
Ranking
Position
Agilent ID Gene Description Access
Number
1 A_23_P213424 ENC1 Ectodermal neural cortex 1 (with BTB-like domain) NM_003633
2 A_23_P24515 ACAT1 Acetyl -coenzyme A acetyltransferase 1 NM_000019
3 A_23_P24716 TMEM132A Transmembrane protein A NM_017870
4 A_23_P40309 SNRPB2 Small nuclear ribonucleoprotein polypeptide B NM_003092
5 A_23_P13663 FAM60A Family with sequence similarity 60, member A NM_021238
6 A_23_P142872 TCF7L1 Transcription factor 7-like 1 NM_031283
7 A_23_P47843 DDX55 DEAD(Asp-Glu-Ala-Asp) box polypeptide 55 NM_020936
8 A_23_P114282 MCTS1 Malignant T cell amplified sequence 1 NM_014060
9 A_23_P103149 ACO2 Aconitase 2 NM_001098
10 A_23_P207999 PMAIP1 Phorbol-12-mystirate-13-acetate-induced protein 1 NM_021127
11 A_23_P63584 AHCTF1 AT hook containing transcription factor NM_015446
12 A_23_P22086 LOC649828 Similar to adenosylhomocysteinase hidrolase (S-adenosyl-L-homocysteine) NW_927818
13 A_23_P88522 NMB Neuromedin B NM_021077
14 A_23_P256413 CMTM7 CKLF-like MARVEL transmembrane domain containing 7 NM_138410
15 A_23_P153615 MADCAM1 Mucosal vascular addressin cell adhesion molecule 1 NM_130760
16 A_23_P112412 TEX10 Testis expressed 10 NM_017746
17 A_23_P209070 LG14 Leucine rich repeat LGI family BC087848
18 A_23_P123343 NUDCD1 NudC domain containing 1 NM_032869
19 A_23_P163179 CALM1 Calmodulin 1 (phosphorilase kinase, delta) NM_006888
20 A_23_P253412 MRLP50 Mitochondrial ribosomal protein L50 NM_019051
21 A_23_P34018 RPL39 Ribosomal protein L30 NM_001000
22 A_23_P70827 KIAA1549 Unknown function AL136736
23 A_23_P113634 CBFB Core-binding factor beta, subunit of dimeric polyomavirus enhancer binding
transcription factor
NM_001755
24 A_23_P30464 PRR7 Proline rich 7 (Synaptic) NM_030567
25 A_23_P37375 RPS6KA5 Ribosomal protein S6 kinase A5 NM_004755
26 A_23_P48771 C14orf159 Chromosome 14 open reading frame 159 NM_024952
27 A_23_127175 SAR1A SAR gene homolog A NM_020150
28 A_23_P141180 TOM1L2 Target of myb-like 2 AK055959
29 A_23_P69399 MST1 Macrophage stimulating 1 protein NM_020998
30 A_23_131846 SNAI1 Snail 1 homolog NM_005985
31 A_23_P121657 HS3ST1 Heparan sulphate D-glucodaminyl 3-O-sulfotransferase NM_005114
32 A_23_P33027 MLXIP MLX interacting protein NM_014938
33 A_23_123343 NUDCD1 NudC domain containing 1 NM_032869
34 A_23_P108676 TMEM166 Transmembrane protein 166 NM_032181
35 A_23_103201 PNRC2 Proline rich nuclear transcription co-activator 2 NM_017761
36 A_23_P51269 CD641036 Protein with high similarity to BTF3 CD641036
37 A_23_P123330 RPL30 Ribosomal protein L30 NM_000989
38 A_23_P252118 POLB DNA polymerase beta NM_002690
39 A_23_P215517 KLHL7 Kelch-like 7 BC00955
40 A_23_P145194 BYSL Bystin-like protein NM_004053
41 A_23_P134274 POP7 Processing of precursor 7, ribonuclease protein subunit NM_005837
42 A_23_P70915 ORAI2 ORAI calcium release-activated calcium modulator 2 NM_032831
43 A_23_P156890 TCF21 Transcription factor 21 NM_003206
44 A_23_P51906 PFDN2 Prefoldin subunit 2 NM_012394
45 A_23_P114232 PRDX4 Peroxiredoxin 4 NM_006406
García-Bilbao et al. BMC Cancer 2012, 12:43
http://www.biomedcentral.com/1471-2407/12/43
Page 5 of 13used in this bioinformatics context, reporting good
results both in time and in relevant genes [27]. CFS
addresses two fundamental issues, avoid redundancy
and irrelevancy in the selected subset of features. There-
fore CFS is configured as the internal selector of rele-
vant genes. Gene expression data may provide
information about various relationships between genes,
which often can be viewed as networks. Hence, using
the filtered data, high confiability Bayesian networks
were carried out. We performed 1, 000 random sam-
plings of our database and in each of them we applied
the CFS technique, inducing a k-dependence Bayesian
classifier (kDB) for each intermediate dataset (reduced
to the genes found by CFS) each time [31]. This way,
the genes most times configured throughout the struc-
tures were identified. Table 2 shows a list of the 20
most recurrent genes obtained. The most robust
statistical dependences obtained from the whole experi-
ment were jointly gathered into a Bayesian network
(Figure 2).
From the visualization of the Bayesian network, we
selected 10 genes with an altered expression between
tumoral and non-tumoral samples.
Quantitative real-time PCR
Quantitative real-time PCR is a commonly used valida-
tion tool for confirming gene expression results obtained
from microarray analysis. Expression levels of the differ-
entially expressed genes were measured using TaqMan
reverse transcription reagents (Applied Biosystems) and
Platinum Quantitative PCR Supermix-UDG with ROX
(Invitrogen). The reaction was performed in MyiQ Sin-
gle-Colour Real-Time PCR Detection System (Biorad) as
follows: 1 cycle at 95°C for 2 min, following 40 cycles of
Table 1 Consensus ranking of the 8,104 probes. In this table the first 50 genes are represented. (Continued)
46 A_23_P215525 OSBPL3 Oxysterol binding protein like 3 NM_015550
47 A_23_P27867 PLAUR Plasminogen activator, urokinase receptor NM_002659
48 A_23_P157405 CHCHD2 Coiled-coil-helix-coiled domain containing 2 NM_016139
49 A_23_P118102 NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex NM_004548
50 A_23_P78423 ATP5A1 ATP synthase H + transporting mitochondrial F1 NM_001001937
In this table the first 50 genes are represented
Table 2 Selected genes. This table represents the first 20 probes identified as the most selected ones.
Times
selected
Agilent ID Gene Description Access
Number
961 A_23_P24515 ACAT1 Acetyl -coenzyme A acetyltransferase NM_000019
820 A_23_P213424 ENC1 Ectodermal neural cortex 1 (with BTB-like domain) NM_003633
567 A_23_P24716 TMEM132A Transmembrane protein A NM_017870
547 A_23_P256413 CMTM7 CKLF-like MARVEL transmembrane domain containing 7 NM_138410
512 A_23_P7353 LARP2 La ribonucleotide domain family member 2 NM_178043
435 A_23_P153615 MADCAM1 Mucosal vascular addressin cell adhesion molecule 1 NM_130760
330 A_23_P26717 RPL23 Ribosomal protein L23 NM_000978
310 A_23_P13663 FAM60A Family with sequence similarity 60, member A NM_021238
287 A_23_P47843 DDX55 DEAD(Asp-Glu-Ala-Asp) box polypeptide 55 NM_020936
275 A_23_P13102 CASP12 Caspase 12 NM_014383
273 A_23_P35521 P4HA1 Proline 4-hidroxylase alpha plypeptide NM_000917
267 A_23_P27964 HOMER-3 Homer neuronal immediate early gene 3 NM_004838
249 A_23_P40309 SNRPB2 Small nuclear ribonucleoprotein polypeptide B NM_003092
246 A_23_38262 ELAC2 ElaC homolog 2 NM_018127
238 A_23_P113634 CBFB Core-binding factor beta, subunit of dimeric polyomavirus enhancer binding
transcription factor
NM_001755
233 A_23_P210253 DGKD Diacylglycerol kinase delta NM_003648
221 A_23_P33075 LO8961 Similar to c-Mer protooncogen tyrosine kinase (human MERTK) LO8961
221 A_23_P131846 SNAI1 Snail 1 homolog NM_005985
218 A_23_P206268 TRAPPC2L Trafficking protein particle complex 2-like NM_016209
208 A_23_P35125 SF3B4 Splicing factor 3b (SF3B) subunit 4 NM_005850
This table represents the first 20 probes identified as the most selected ones
García-Bilbao et al. BMC Cancer 2012, 12:43
http://www.biomedcentral.com/1471-2407/12/43
Page 6 of 1395°for 10 s and 60°for 1 min. Results were analysed with
the MyIQ™ (Biorad) software to obtain the Cq values for
each sample. A ΔCq value was calculated reflecting the
difference between the average Cq of the replicate sam-
ples obtained for the control gene (18S) and the average
Cq of the replicate samples obtained for the test gene to
be validated. Using these ΔCq values as the raw expres-
sion value in the qPCR experiment, we first determined
the median ΔCq for all the non-tumoral control samples.
Next, we calculated the difference between the ΔCq of
each test sample and the ΔCq values of the controls, thus
obtaining a set of ΔΔCqdiff values for each gene.
Machine learning validation using a new cohort of
samples
In order to validate the classification power of the bio-
marker panel, we tackled the classification of a new
cohort of samples, but using only the expression of the
genes previously identified within the panel [33]. The
new microarrays were produced following the same pro-
tocols and technologies presented in previous sections.
There were a total of 36 tissue samples: 14 non-tumoral,
2 stage A, 11 stage B, 3 stage C and 6 stage D (Addi-
tional file 2). To follow the rationale of the paper, all
the 22 tumoral samples were grouped together into a
single category labeled tumoral. All the 36 samples (14
non-tumoral and 22 tumoral) were hybridised against
the same reference pool previously described (see
Experimental Design section). These microarray data are
available in http://www.ebi.ac.uk/arrayexpress under the
accession number E-MTAB-770.
Three different classification paradigms were used to
validate the panel: naïve Bayes (nB), support vector
machines (SVM) and k-nearest neighbors (k-NN) with k
= 3 to avoid ties [34]. In order to assess the classifica-
tion performance of each of the mentioned paradigms,
we used a leaving-one-out cross-validation scheme
(LOOCV). This validation scheme estimates the accu-
racy of a given classification model by inducing the
same number of classifiers as the dataset is comprised
of. Each model is built with all the cases but one and
tested on the left out case. The model accuracy is finally
estimated as the average accuracy over all these classi-
fiers. In addition to the estimated classification accuracy,
the area under the receiving operating characteristic
(ROC) curve or AUC was also considered.
Biological pathway analysis
As an exploratory approach, we used Ingenuity Path-
ways Analysis (IPA) software (Ingenuity
® Systems,
http://www.ingenuity.com) to assess the involvement of
the relevant genes in known molecular pathways and
networks. Briefly, a dataset containing the gene names
was uploaded into the software. Networks were
generated as graphical representations of the molecular
relationships between genes. Genes are represented as
nodes and the biological relationship between two nodes
is represented as an edge (line). Nodes are displayed
with various shapes that represent the functional class
of the gene product. Right-tailed Fisher’s exact test was
used to calculate a p-value determining the probability
that each biological function and/or disease assigned to
our dataset was due to chance alone.
Results
The graphical dependency structure reported in Figure 2
gathers a total of 14 genes with an occurrence threshold
greater or equal than t = 100. From all of them, ENC1
(ectodermal-neural cortex, with BTB-like domain) results
in a core gene that shows dependences with 9 out of the
14 genes represented. This gene, also known as NRPB or
PIG10, is a peptidase that regulates the expression of CEA-
CAM5, CASP3 or Erk1/2 [35]. It also binds to actin and
retinoblastoma 1 (RB1) gene [36]. Regarding its role in
colon cancer, Fujita et al. [37] suggested that ENC1 is
regulated by b-catenin/TCF pathway and its altered
expression may contribute to colorectal carcinogenesis by
suppressing differentiation of colonic cells. In the down-
stream dependences, we find ACAT1 (acetyl-coenzyme A
acetyltransferase 1), which has been shown to play a pivo-
tal functional role in the intestinal absorption of choles-
terol, hepatic secretion of VLDL, biosynthesis of steroid
hormones, production of cholesterol esters in macro-
phages in atheroma and secretion of biliary cholesterol
[38]. Next, TMEM132A (transmembrane protein 132A)
has been described as an important factor of cell survival
in regulating certain endoplasmic reticulum stress-related
gene expression in neuronal cells [39]. It has not been
related to carcinogenesis or cancer progression as yet.
MADCAM1 (mucosal vascular addressing cell adhesion
molecule 1) is preferentially expressed in endothelial cells
of the intestinal mucosa, submucosa and Peyer’s patches
[40]. High expression of this and other adhesion molecules
has been correlated with prolonged disease-free survival in
CRC [41]. It interacts preferentially with the leukocyte
beta7 integrin LPAM-1 (alpha4beta7), L-selectin, and
VLA-4 (alpha4beta1) on myeloid cells to direct leukocytes
into mucosal and inflamed tissues. Two other reported
genes, MCTS1 (malignant T cell amplified sequence 1)
and SNRPB2 (small nuclear ribonucleoprotein polypeptide
B) have been related to proliferation. MCTS1 was consid-
ered as a possible oncogene [42], and SNRPB2 is an essen-
tial component of the mRNA splicing machinery playing a
role in cell proliferation [43,44].
Although not directly influenced by ENC1,w ei d e n t i -
fied RPL23 (ribosomal protein L23). This gene regulates
TP53 [45] among other genes and it takes part in G1/S
phase transition.
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Page 7 of 13Finally, the Bayesian model also revealed other recur-
rent genes, FAM60A (family with sequence similarity
60, member A), CMTM7 (CKLF-like MARVEL trans-
membrane domain 7) and DDX55 (DEAD (Asp-Glu-
Ala-Asp) box polypeptide), currently not reported to be
involved in cancer progression.
These 10 genes were subjected to IPA software, where
they were mapped to networks defined by Ingenuity’s
database (Figure 3). Therefore, 6 of the genes (ENC1,
ACAT1, MSTC1, MADCAM1, RPL23 and SNRPB2) were
found to be associated with cancer, genetic disorder or
reproductive system disease within the same network.
The rest of the genes were involved in different networks,
with dissimilar biological functions associated to them:
the DDX55 gene is related to free radical scavenging,
metabolic disease and renal and urological disease;
TMEM132A is linked to post-translational modification,
protein folding and cell death and FAM60A is connected
to skeletal and muscular system development and func-
tion, tissue development and cell death. CMTM7 involve-
ment in any biological process has not been reported yet.
Experimental validation by qRT-PCR
This technique provides quantitative assessment of the
relative abundance of specific transcripts using gene-
specific primers [46]. To examine the reliability of our
microarray results, we did a qPCR experiment with the
genes identified. This validation was carried out with 15
new samples (4 non-tumoral and 11 tumoral samples).
For each gene and phenotype, ΔΔCqdiff values were cal-
culated (see Methods), and the median values of these
ΔΔCqdiff, together with the expected gene expression
activities are shown in Table 3. As a dispersion measure
of the results, the values for the first and third quartile
of each group of values are also shown. These results
confirmed that the expected gene expression profiling as
measured by microarray quantitation is validated by the
qPCR experiment for 7 of the genes analysed.
Machine learning validation by different classification
paradigms
The pre-processing of the new cohort of 36 microarrays
was done in accordance with the protocols also used in
the original arrays. After reducing the data matrix to just
the 10 genes gathered in the panel of biomarkers, a
LOOCV using three different classification paradigms
was performed. The performance of the gene set was out-
standing with an estimated accuracy of 94.45% and AUC
of 0.994, 0.995 and 0.971 for nB, SVM and k-NN, respec-
tively. In order to test the subset of genes that had
already passed the qPCR validation stage, we retained
only those seven genes (see Table 3) and redid the
experiment. The results in this case reported the same
estimated accuracy of 94.45% with very slight differences
in terms of AUC (0.997, 0.955 and 0.974 for nB, SVM
and k-NN respectively). Specially relevant is the fact that
for every of these estimations the specificity score was 1,
i.e. the false positive rate (FPR) was zero. In terms of the
confusion matrix, this fact implies that all the non-
tumoral samples were always correctly classified as non-
tumoral, whereas just two of the tumoral samples were
classified as non-tumoral (sensitivity score of 0.909).
ENC1 
DDX55
FAM60A
MCTS1
TMEM132A
RPL23
PMAIP1
SNRPB2
MADCAM1
ACAT1
UBE3B
RPS6KA5
CMTM7
UBE1L DDX55
Figure 2 Graphical structure of the high-reliable dependences network. The occurrence threshold was set in 100 out of the total 1, 000
main bootstrap iterations. The constant presence of this core of genes gives the criterion to select them as the final biomarker panel.
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Sporadic CRC is one of the most frequent types of can-
cer in our society and current treatment has the best
effect on the early-stage disease. Colorectal carcinogen-
esis involves a network of genetic alterations that affect
DNA repair genes, oncogenes and tumour suppressor
genes. An important objective in nowadays research is
the discovery of new biomarkers that can detect colon
tumours in early stages. Recently, molecular studies
have extended the opportunity for testing new potential
markers as only a few markers can be recommended for
practical use in clinic [47]. Gene expression analysis
d. Network 4
a. Network 1 b. Network 2
c. Network 3
Figure 3 Main networks obtained for the most relevant genes. These networks were generated through the use of Ingenuity Pathways
Analysis www.ingenuity.com. Genes are represented as nodes and the biological relationships between 2 nodes is represented as an edge (line).
The functional analysis of the networks identified the biological functions and/or diseases that were most significant to the molecules in each
network. In this sense, network 1 is associated to Cancer, Genetic disorder and Reproductive system disease; network 2 is associated to Free
radical scavenging, Metabolic disease and Renal and Urological Disease; network 3 is associated to Post-translational Modifications, Protein
folding and Cell death and network 4 is associated to Skeletal and Muscular System Development and Function, Tissue Development and Cell
Death. Molecules in black represent the genes from our dataset. Dash lines represent indirect relationships (2000-2010 Ingenuity Systems, Inc).
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Page 9 of 13studies have resulted in many new insights in cancer
biology and mRNA expression analysis is turning out to
be a very useful tool for cancer classification, cancer
diagnosis and disease outcome prediction [48].
The main objective of our study was to develop a ten-
tative model for the classification of non-tumoral and
tumoral samples, based on their expression profiles.
One important requirement in the screening of CRC is
that the test used should have high sensitivity and speci-
ficity, namely, a low number of false-negative and false-
positive results. Our approach combined a resampling
method with an inner feature selection technique and a
Bayesian k-dependence classifier to obtain a relevant
gene subset. By means of this gene panel, different
supervised classifiers were induced to classify 36 newly
unseen samples. To estimate the performance of the
models, a leave-one-out cross validation (LOOCV) [49]
was performed. The estimation achieved a 94.45%
degree of accuracy with associated AUC values between
0.997 and 0.955, with only two misclassified samples in
the confusion matrix (specificity = 1, sensitivity = 0.909
using only the 7 genes validated by the qPCR). Non-
tumoral samples were always distinguished from the
tumoral ones. These results over a set of unseen sam-
ples flawlessly support the joint classification ability of
the identified biomarker panel found using the initial
cohort of samples
We used Ingenuity Pathways Analysis software (Inge-
nuity
® Systems, http://www.ingenuity.com) in an
attempt to decipher the involvement of these genes in
biological networks. Although no direct relationships
were found between our set of validated genes, all of
Table 3 qPCR output values and expected activity for 7
genes from the relevant gene list
Gene Symbol Median 1st-quartil 3rd-quartil Expected
ENC1 2.12 1.71 3.19 UP
ACAT1 -1.63 -1.99 -0.83 DOWN
TMEM132A 2.80 2.42 3.63 UP
CMTM7 1.65 0.19 2.58 UP
FAM60A 0.93 0.34 1.35 UP
MADCAM1 -2.48 -5.10 -0.21 DOWN
DDX55 1.11 0.53 1.28 UP
Figure 4 Molecular relationships between genes. This network is a graphical representation of the relationships between the validated genes
obtained from the analysis and other molecules. Molecules in blue represent the 7 validated genes (see legend in figure 4) Genes involved in
colon cancer are highlighted in green. Only human relationships are presented. All edges are supported by at least 1 reference from the
literature, textbook or canonical information stored in Ingenuity’s Knowledge Base (2000-2011 Ingenuity Systems, Inc).
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Page 10 of 13them, except for CMTM7, were involved in a network
were TNF (tumour necrosis factor) and secondly RELA
(v-rel reticuloendotheliosis viral oncogene homolog A
(avian)) played a central part (Figure 4). Both genes are
related to inflammatory processes and take part in CRC
metastasis canonical pathway [50]. According to IPA’s
Knowledge Base functional analysis, from the 19 genes
implicated in this network, 14 are involved in cancer
with a p-value of 1.14E-05. Among them, ENC1 and
ACAT1 are directly involved in this disease as previously
mentioned [33,37,51]. Expression of ENC1 was exam-
ined in colon cancer samples and their corresponding
non-cancerous tissues using semiquantitative RT-PCR,
and its expression was increased in 17 of the 24
tumours analysed [37]. These results subscribe our find-
ings in microarray analysis, where this gene showed an
upregulation in tumoral samples, comparing to the non-
tumoral counterparts. Moreover, Figure 4 shows that
ENC1 interacts with RB1 (retinoblastoma 1) [36], which
acts as a tumour suppressor gene through the regulation
of transcription of MYC (v-myc myelocytomatosis viral
oncogene homolog (avian)) and other genes involved in
growth [52]. Regarding ACAT1, it has been proposed
that it is constitutively expressed and likely functions to
maintain the intracellular balance of free and esterified
cholesterol [53]. In our microarray analysis we observed
that this gene was downregulated in tumoral samples.
Ancona et al. performed a microarray analysis and
observed that ACAT1 was downregulated in tumoral tis-
sue, comparing to normal mucosa [33].
Others, as TMEM132A or MADCAM1 are indirectly
involved in tumorigenesis through protein-protein inter-
actions with HSPA5 (heat shock 70 kDa protein 5 (glu-
cose-regulated protein, 78 kDa)) and SELL (selectin L)
respectively. FAM60A is also implicated in the tumori-
genesis process through protein-DNA interaction with
E2F1 (E2F transcription factor 1) and finally, DDX55
expression is indirectly controlled by SOD2(superoxide
dismutase 2, mitochondrial), which is directly involved
in neoplasia and carcinogenesis. Furthermore, from the
14 genes that IPA found to be involved in cancer, 8
genes are specifically related to CRC, with a p-value of
7.22E-06 (Table 4) and our Bayesian model’sc o r eg e n e ,
ENC1, among them.
Finally, Figure 4 shows that there are direct or indirect
molecular relationships between the other genes from
the panel and those involved in cancer. However, until
now no public data has been reported regarding the role
of these genes in cancer progression. Nevertheless, the
whole gene panel (7 genes) is required as a group to
identify new unseen samples as tumoral or non-tumoral
with 96.92% accuracy.
Conclusions
Consensus approaches are alternative techniques that try
to overcome the technology intrinsic data noise in
microarray experiments. In the present paper, we
applied a supervised consensus gene selection method,
aiming to add robustness to the biomarker identification
procedures by means of DNA microarrays. Throughout
this paper, from the starting feature selection to the
final biological validations, we have exposed a battery of
techniques, to add reliability and proofs to the results.
We would like to emphasize the posterior validation of
the findings by means of qPCR analysis with an extra
set of samples not used in the previous statistical stage.
In conclusion, we have achieved a tentative biomarker
consisting in a panel of 7 genes capable of correctly
classifying cancerous and non-cancerous colon samples.
This biomarker could constitute the basis of a new tool
with high potential for CRC diagnosis. Future work will
comprise the application of this pipeline to the analysis
of each severity stage independently.
Additional material
Additional file 1: Clinical sampled data. M = male; F = female.
Additional file 2: New cohort of samples (clinical data).
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